as declared in thestreet
Biomarin Hemophilia Gene Therapy Advances on Strong Study Results
Biomarin Hemophilia Gene Therapy Advances on Strong Study Results
Roche Beats First-Half Forecasts as Cancer Drug Sales RiseThe Swiss pharmaceuticals company confirms a forecast for full-year sales to increase in the low to mid-single digits, and for earnings per share to grow faster than revenue.
moreover from globenewswire
BioMarin Provides Positive Proof-of-Concept Data for BMN 270 Gene Therapy in Hemophilia A in Late Breaking Oral Presentation at the World Federation of Hemophilia (WFH) 2016 World Congress Nasdaq:BMRN
BioMarin Provides Positive Proof-of-Concept Data for BMN 270 Gene Therapy in Hemophilia A in Late Breaking Oral Presentation at the World Federation of Hemophilia (WFH) 2016 World Congress Nasdaq:BMRN
6 of 7 High Dose Patients Show Factor VIII levels above 50%, 7th patient above 10%No Clinically Relevant Sustained Rises in ALTPhase 2b Study to Begin Mid-2017 for Potential Accelerated Approval FilingConference Call and Web-cast with Slides to be Held Wednesday, July 27th at 4:05pm ETSAN RAFAEL, Calif., July 27, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today positive interim results of an open-label Phase 1/2 study of BMN 270, an investigational gene therapy treatment for severe hemophilia A at the XXXII International Congress of the World Federation of Hemophilia (WFH).The data was presented in the Late Breaking Gene Therapy session by John Pasi, Professor of Haemostasis and Thrombosis, Barts and the London School of Medicine, Honorary Consultant Haematologist, The Royal London Hospital, and a lead investigator of the study.The data presented at the congress is an update since the Company reported initial results on this same study on April 20, 2016.
coupled with forbes
BioMarin Gene Therapy Yields Dramatic Results In Hemophilia
BioMarin Gene Therapy Yields Dramatic Results In Hemophilia
No comments:
Post a Comment